Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
Angioplasty is not a new procedure – doctors have been widening obstructed arteries with balloons since the 1960s. But for years the medtech industry has been plagued with what Jeff Mirviss, president of Boston Scientific’s interventional peripheral biz, calls the procedure’s Achilles heel: Restenosis.
For patients treated with bare balloons, half must have the procedure done again because their arteries have re-clogged. Stents improved that rate to 1 of every 3 or 4 patients, Mirviss told Drug Delivery Business News. But drug-coated balloons designed to control scar tissue formation can bring the rate down to 1 in 20 patients. Read more
Baxter chairman & CEO Joe Almeida says he’s prepared to pull the trigger on a major acquisition worth as much as $7.5 billion, but any deal has to pass the healthcare giant’s M&A criteria.
Speaking with analysts earlier this week during a conference call to discuss Deerfield Park, Ill.-based Baxter’s 1st-quarter results, Almeida said that the transformation begun after he took the reins at the beginning of last year puts the company in position to execute a deal. Read more
Titan Medical said today that it’s spiking talks with Chinese distributor Longtai Medical over its Sport robot-assisted surgery platform so it can focus on winning regulatory approvals in the U.S. and Europe.
Back in October 2015, Toronto-based Titan inked a private placement deal with Longtai, a subsidiary of Chinese medical device distributor Ningbo Long Hengtai International Trade Co., that could have ended up being worth more than $24 million. Read more
Medtronic and Abbott could take another run at taking their high-end stents off the Indian market, after the Indian National Pharmaceutical Pricing Authority this week rejected their applications to withdraw.
Earlier this month, Medtronic and Abbott said they would look to withdraw select high-value coronary stents from the Indian market in light of cost caps imposed by the NPPA. Medtronic filed to remove its Resolute Onyx stent from the market, while Abbott filed to remove both its Absorb and Alpine stents. Read more
Olympus said today that its American subsidiary plans to acquire Image Stream Medical for an undisclosed amount.
Littleton, Mass.-based Image Stream makes software designed to connect hospital imaging equipment and systems. Center Valley, Pa.-based Olympus Corp. of the Americas said it aims to build a global systems integration platform using the Image Stream tech. Read more